To evaluate the osteopontin (OPN) protein expression levels in breast carcinomas to determine if they correlate with mammographic appearances such as calcifi cations.
BREAST IMAGING : Osteopontin Expression in Breast Carcinoma
Wang et al 239 women with invasive breast carcinoma that was detected during screening mammography and obtained written informed consent from 158 living patients. The institutional review board ruled that the relatives of 12 women who died of breast cancer before the start of this study were exempt from providing written informed consent.
Patients were excluded when we could not obtain archival paraffi n-embedded tumor specimens, clinical information, or available preoperative mammograms for analysis, and patients with evidence of disease within 1 month after primary surgery were excluded. Furthermore, patients with only carcinoma in situ or with bilateral breast cancer were excluded from this study. Of the 170 patients, a total of 29 were excluded because of the reasons noted above. The associations of clinicopathologic features (tumor subtype, TNM stage, axillary lymph node metastasis, and tumor grade) with mammographic calcifi cations and mammographic features (mass, calcifi cation, architectural distortion, and asymmetric density) with HER2/neu overexpression in these 141 patients were evaluated in our previous study ( 5 ) . Additionally, associations of OPN expression with clinicopathologic features (triple-negative subtype, TNM stage, histologic subtype, and tumor grade) in 53 of these patients have been reported previously ( 13 ) . A breast and gynecologic pathologist (H.L., 30 years of experience) have increasingly aggressive behavior and worse prognosis ( 11, 12 ) . Our previous study ( 13 ) showed that mean OPN levels were signifi cantly lower in the triple-negative breast cancers than in the non-triple-negative subtype. As a metastasis-associated small integrinbinding ligand N -linked glycoprotein family member, OPN appears to be a plausible mediator involved in the process of calcifi cation in breast cancer tissues ( 14 ) . Bellahcène and Castrovovo ( 15 ) reported that OPN could play a role in the formation of breast calcifications often associated with malignant tumors and speculated that the expression of OPN may play a critical role in facilitating spread of tumor cells to the bone microenvironment.
Therefore, identifi cation of the OPN expression levels in conjunction with breast radiologic calcifi cations may provide additional support for OPN functioning and a better understanding of mammographic calcifi cations. However, to our knowledge, no study exists about the association of OPN expression and mammographic calcifi cations. The purpose of the study was to evaluate OPN protein expression levels in breast carcinomas to determine if they correlate with mammographic appearances such as calcifi cations. ( 2 ) , and invasive breast carcinomas (3) (4) (5) . There is a considerable need to identify new markers associated with progression and tumor aggressiveness in conjunction with mammographic features such as calcifi cations to provide more clues that would help breast specialists make treatment decisions preoperatively.
Materials and Methods

Patients
Elevated expression of osteopontin (OPN) has been observed in several cancers (6) (7) (8) . Studies have shown that elevated OPN expression is correlated with poor prognosis in patients with breast cancer ( 9, 10 ) . On the basis of three common molecular markers, estrogen receptor, progesterone receptor, and HER2/neu analysis, breast tumors can be classifi ed into the categories of luminal, HER2/neu, and "triple-negative" (ie, cancer that is estrogen receptor, progesterone receptor, and human epidermal growth factor receptor negative) phenotypes, and, in this order,
Implication for Patient Care
The association of OPN expresn sion with mammographic calcifications from this study can be used to more precisely predict patient outcome and guide the therapeutic approach preoperatively for patients with breast cancer.
Advance in Knowledge
Osteopontin (OPN) status of n patients with breast cancer is associated with the presence of calcifi cations ( P = .012), most of which are of pleomorphic morphology ( P = .046), at mammography; spiculated margins of mass at mammography ( P = .02); triple-negative phenotype ( P = .02); and axillary lymph node metastasis ( P , .0001).
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were prepared by omission of the primary antibody. Estrogen receptor, progesterone receptor, and HER2/neu status were assessed by using standard immunohistochemical methods. Immunohistochemical markers were assayed in paraffi n-embedded, formation-fi xed tissue stained with hematoxylin-eosin and by using antibodies to the proteins of estrogen receptor, progesterone receptor, and HER2/neu (Dako, Glostrup, Denmark). For estrogen receptor and progesterone receptor, receptor positivity was based on more than 10% of cells testing positive. HER2/neu was assessed with immunohistochemistry and was scored on a qualitative scale from 0 to 3+, based on interpretation of staining, with 0 and 1+ classifi ed as HER2/ neu negative and 3+ as HER2/neu positive. Tumor specimens that showed an intermediate HER2/neu staining score of 2+ were further assayed with fl uorescence in situ hybridization (Vysis , Des Plaines, Ill) to determine the more appropriate classifi cation. All samples that had intense, complete, membranous staining in more than 10% of invasive neoplastic cells determined with immunohistochemistry or the presence of HER2/neu gene amplifi cation determined by using fl uorescence in situ hybridization were considered HER2/ neu positive. Therefore, in comparing groups, HER2/neu positive, luminal subtypes were combined into a single non-triple-negative group and were compared with the triple-negative group.
Evaluation of Anti-OPN Immunohistochemical Staining
Immunohistochemical staining was evaluated and scored by two pathologists (H.L. and X.Z., 30 and 35 years of experience, respectively) who worked independently and were blinded to clinical information. All pathologic specimens were evaluated during 1 month, and agreement on the staining scores was by consensus. The overall amount of staining for OPN was determined on the basis of staining intensity and proportion (or extent) of stained tumor cells as described by Tuck et al (18) (19) (20) . The proportion score represented the both radiologists had to agree on an interpretation before the results were recorded. The mammograms were reviewed according to the analytic criteria of the Breast Imaging Reporting and Data System ( 16, 17 ) . Mammographic fi ndings were categorized as mass, calcifi cation, architectural distortion, and asymmetric density. For carcinomas manifesting as masses at mammography, we evaluated the shape, margin, density, and associated fi ndings. For carcinomas with calcifi cations at mammography, morphology and distribution were evaluated. Morphologic aspects of calcifi cation were classifi ed into four groups: pleomorphic, fi ne linear, punctuate, or coarse calcifi cations. Distribution features were classifi ed as clustered, segmental, regional, linear, or diffuse.
Immunohistochemical Staining Method
OPN expression was determined by using immunohistochemical staining of 141 tissue slices by using a mouse antihuman monoclonal osteopontin antibody (MAb1433; R&D Systems, Minneapolis, Minn). Detection was performed with streptavidin-peroxidase complex. Histopathologic assessment was performed in paraffi n sections, 4-6 m m in thickness. Immunohistochemistry procedure was performed in slices having been incubated in 3% H 2 O 2 in methanol for 10 minutes, followed by washing in 0.01 mmol/L phosphate-buffered saline and treatment with 1% normal goat serum for 10 minutes at room temperature (the latter to block nonspecifi c binding of the antibody). The slides were then incubated with the primary mouse antihuman monoclonal antibody (MAb1433, dilution 1:200) for 2 hours at 4°C. Sites of primary antibody binding were identifi ed by incubating blots with horseradish peroxidase-conjugated antigoat immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, Calif) (dilution 1:250), followed by reaction with substrate 3,3
9 diaminobenzidine tetrahydrochloride. Nonspecifi c staining was blocked by incubating slides with 5% normal goat serum. Normal gallbladder was used as a positive control for OPN. Negative controls for immunostaining reevaluated pathologic features. The tumor subtypes of invasive carcinoma were classifi ed as ductal carcinoma and others. Other invasive carcinomas included medullary, mucinous, or lobular carcinomas. Tumor grade of invasive carcinomas was classifi ed according to the Scarff-Bloom-Richardson system. On the basis of the frequency of cell mitosis, tubule formation, and nuclear pleomorphism, invasive carcinoma was classifi ed as grade 1 (low), grade 2 (moderate), or grade 3 (high). Presence of lymph node metastases was reviewed for each patient. Tumor stage was determined according to the Union Internationale Contre le Cancer TNM system. All three molecular markers (estrogen receptor, progesterone receptor, and HER2/neu) of these patients were available. Clinical data were collected from the medical fi les. Conventional clinical features were evaluated, including age, menopausal status, pathologic grading, and lymph node metastasis. All 141 patients included in this study had primary breast cancer without distant metastases at the time of diagnosis. The median age of the patients was 53 years (age range, 29-82 years).
Mammography
Mammograms were obtained with a mammographic system (Gold Standard DR 17; Pan-Pacifi c Enterprises, Brewster, NY). Technical specifi cations included the following: pixel size, 143 µm; number of pixels, 9 million; x-ray sensing surface, 3121 3 3121; receptor type, hydrogenated amorphous silicon . The standard craniocaudal and lateral views were obtained in all patients. Full-resolution digital mammography of calcifi cations included orthogonal magnifi cation projections, usually craniocaudal and mediolateral projections. Cone-down magnifi cation views were obtained when necessary. All mammograms were evaluated by two experienced breast radiologists (A.O. and M.H., 2 and 11 years of breast imaging experience, respectively). The two radiologists reviewed all mammograms randomly during 1 month without knowledge of the clinicopathologic fi ndings; 
Statistical Analysis
One author (G.M.) performed all statistical analyses by using software (SPSS, version 11.5; SPSS, Chicago, Ill). The x 2 and Fisher exact tests were used to evaluate the association of OPN expression with mammographic and clinicopathologic features. All statistical tests were two-sided, and statistical significance of observed difference was set at P , .05.
Results
Clinicopathologic Features of Breast
Carcinoma according to OPN Expression OPN-positive expression was detected in 65% (92 of 141) of the invasive ductal carcinomas ( Table 1 , Fig 1 ) . Of the 141 patients, 121 (86%) had invasive ductal carcinoma, nine (6.4%) had invasive mucinous carcinoma, six (4.0%) had invasive lobular carcinoma, and fi ve (3.5%) had medullary carcinoma. Tumor grading result was as follows: grade 1 in 33 , grade 2 in 88, and grade 3 in 20 of 141 invasive breast tumors.
Axillary lymph node metastases were more common in cancers with OPN-positive expression than in those with OPN-negative expression (81.5% vs 38.8%, P , .0001). There was a borderline signifi cance between menopausal status and OPN expression (53.3% vs 34.7%, P = .054). OPN-positive expression was signifi cantly more frequent in patients with triple-negative phenotype than in those with non-triple-negative breast carcinomas (26% vs 8.1%, P = .02). There was no signifi cant difference in tumor subtypes, tumor grades, estrogen receptor status, progesterone 
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information for the decision of treatment strategy before operation. Thurfjell et al ( 21 ) found that small invasive breast cancers (1-9 mm) manifesting at mammography as casting or pleomorphic calcifi cations alone had a signifi cantly worse prognosis than other types, and Tabar et al ( 22 ) obtained similar results, in that mammographic casting-type calcifi cations had a worse prognosis for survival in tumors of 14 mm or smaller, especially for those smaller than 9 mm. Furthermore, Tot ( 23 ) believed that the extent and distribution of lesions in breast carcinomas were important biologic prognostic factors that infl uenced the type and results of surgical intervention, as well as the propensity for metastasis. Developing a unifi ed classifi cation schema that incorporates imaging fi ndings such as calcifi cation, molecular subtype, and predictive biomarkers should help to more precisely predict patient outcome. This might also lead to prediction of individuals who will be responsive to a specifi c therapeutic regimen. Our initial observation showed that mammographic calcifi cations were associated with HER2/ neu expression ( 5 ). In fact, Kang et al ( 24 ) found that patients with invasive ductal carcinoma with an extensive intraductal component showed calcifi cations at mammography.
OPN has been detected in 65%-70% of primary breast carcinomas ( 9, 25 ) . We found that 65% of the carcinomas had OPN-positive expression in the current study. Oates et al ( 26 ) reported that the messenger RNA for OPN was expressed at a ninefold higher level in the metastatic Ca2-5-LT1 cell line than in the nonmetastatic parental Rama 37 cell line; thus, increasing the expression of OPN in a previously benign cell line was suffi cient to produce a metastatic phenotype in a rat mammary model. Khan et al ( 27 ) provided evidence that OPN could enhance CD44 messenger RNA expression, increase cell surface expression of CD44 variant forms without a change in messenger RNA levels, and stimulate cell migration in 21NT cells. Furthermore, our data and our previous quantitative results have shown that patients with should prompt a clinician to suspect the level of aggressiveness of breast cancers, thereby assuring that those likely to be potentially the most lethal would in turn be treated in a more aggressive manner from the outset than others. Evaluation of the associations of OPN expression with mammographic calcifi cations may provide more additional
Discussion
We found that OPN status of patients with breast cancer was associated with the presence of calcifi cations, most of which were of pleomorphic morphology, at mammography; spiculated margins of mass at mammography; triplenegative phenotype; and axillary lymph node metastasis. These characteristics ( 45 ) . Further study utilizing multimarker panels to evaluate the associations of these other markers with mammographic calcifi cations will be helpful for clinical decision. Compared with OPN-negative breast cancers, OPN-positive tumors were more likely to have calcifi cations, to be spiculated, to have pleomorphic calcifications, to be a triple-negative phenotype, and to be associated with axillary lymph node metastasis. In the future, breast cancer will be treated on the basis of the molecular features of the patient's tumor. The association between mammographic features and OPN expression may facilitate prognostic assessment and guide the therapeutic approach. Calcifi cations detected during screening mammography are not only of diagnostic value but are of potential use in determining therapeutic options and prognosis.
early stage breast cancer with limited metastatic risk ( 34 ) . Canavese et al ( 35 ) suggested that predictors of axillary node positivity should be developed so as to limit the use of the sentinel lymph node procedure in women at low risk of bearing metastases in the axillary nodes. Our results indicated that OPNpositive expression was associated with the presence of axillary lymph node metastasis ( P , .001), and our previous quantitative analyses ( 13 ) showed that mean OPN levels were signifi cantly higher in lymph node metastases than in the primary tumor ( P = .004). Thus, the association of OPN expression with mammographic calcifi cations may play a role in the prediction of axillary lymph node metastasis.
Our fi ndings provided evidence that OPN-positive cancers were more likely to appear as spiculated masses. Although previous studies have shown that more than 80% of spiculated lesions seen on mammograms have been found to be histologically malignant ( 21 , 36 ) , they also have shown that spiculation is a favorable feature in terms of breast cancer survival (37) (38) (39) . Thus, further study is needed to determine the relationship between spiculated mass and OPN expression. Being a secret protein, a higher level of plasma OPN was detected in patients with metastatic breast cancer than in control patients with early breast cancer or healthy women ( 40 ) . Furthermore, Martinetti et al ( 41 ) reported that OPN serum value was associated with tumor burden and survival in patients with advanced breast cancer. Additional prospective studies are warranted to further evaluate the associations between serum or plasma OPN level and mammographic calcifi cations.
One potential weakness of the current study was the potential for underestimation of statistical difference due to the stratifi cation of the data and subsequent low numbers in some of the categories. The retrospective nature and relatively small sample size presents potential limitations with respect to the interpretation of this study. The development of three-dimensional approaches, such as digital breast tomo-OPN-positive expression develop predominantly triple-negative breast carcinomas ( 13 ) , which are associated with aggressive histology, poor prognosis, and shorter survival ( 28 ) .
In the current study, mammographic calcifi cations were signifi cantly more frequent in carcinomas with OPNpositive expression than in those with OPN-negative expression. Our fi nding was consistent with the fi ndings in other studies that OPN has been detected in high levels in malignant breast tissues with calcifi cations ( 14, 15 ) , which confi rms the hypothesis that aberrant expression of OPN may contribute to the formation of calcifi cations in breast carcinomas ( 15, 29 ) . Our study showed that pleomorphic calcifi cations were more common in carcinomas with OPN-positive expression than in those with OPN-negative expression. These results supply important evidence to support Tabar et al ( 22 ) who note that even small cancers ( , 10 mm) have the potential to be lethal if associated with casting-type calcifi cations. Previous observations that OPN in milk may inhibit crystal growth ( 30,31 ) may account for the granular appearance of this type of calcifi cation. Because OPN expression correlated with a metastatic phenotype and worse prognosis ( 9, 20 ) , it is not surprising that the patients with aggressive tumors frequently had pleomorphic calcifi cations at mammography.
In addition, we found that mammographic calcifi cations as an associated fi nding of mass were more frequent in carcinomas with OPN-positive expression than in those with OPN-negative expression. Given the hypothesis that OPN is a key molecular player involved in lymphatic metastasis of breast cancer ( 32 ) , this fi nding may explain the results that invasive tumors manifesting as mammographic masses with calcification had the highest rate of lymphatic invasion and positive axillary nodes ( 33 ) . Furthermore, new insights on axillary surgery have led to the concept of sentinel lymph node biopsy as an alternative to complete lymphadenectomy for patients with clinically negative lymph nodes. It is mainly dedicated to
